{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:28:01Z","timestamp":1787668081390,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The relationship between chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and type 2 inflammation has led to the use of biologic treatment for uncontrolled cases. As biologic treatment remains a relatively new approach for CRSwNP, systematic assessment and collection of high-quality, real-world data are crucial. This study established the national Global Airways registry to collect longitudinal data over a period of 12 months for patients with CRSwNP treated with biological therapies according to criteria established by the Danish Health Authority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All participating sites conducted systematic assessments of patients with CRSwNP referred for initiation of biologic treatment. Clinical and patient-reported outcome data were collected at baseline and after 6 and 12 months of treatment and were entered in real-time into the Global Airways registry. Comparisons were performed between patients eligible or not eligible for biologic therapy and between pre- and post-treatment timepoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 513 patients were enrolled between November 2022 and December 2024, with 310 receiving treatments with biologics (mepolizumab or dupilumab). Mean [standard deviation (SD)] age in the treatment group was 49.7 (14) years and 66% were male. The median number of previous endoscopic sinus surgeries was 2 (range 1\u201316). Baseline mean (SD) scores were as follows: Nasal Polyp Score (NPS) 4.8 (1.7); Sinonasal Outcome Test (SNOT)-22 68.7 (18.7); Visual Analog Scale (VAS) CRS 84.1 (16); and Sniffin\u2019 Sticks-16 (SST-16) score 4.8 (3). Asthma was present in 204 (66%) patients, with a mean (SD) Asthma Control Questionnaire (ACQ)-5 score of 2.1 (1.5). Among patients with available data at both 6 and 12 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009160), mean SNOT-22 scores improved from 68 to 29 and 24, NPS from 5.1 to 3.0 and 2.4, SST-16 from 4.7 to 9.2 and 10.0, and ACQ-5 from 2.3 to 1.0 and 0.8 (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Global Airways registry was an effective working tool that ensured collection of important real-world data when moving from surgery to biologics. Furthermore, the registry demonstrated the sustained effectiveness of biologic therapy in patients with refractory CRSwNP and provided a robust foundation for defining CRS phenotypes and advancing targeted treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1735943","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:34:26Z","timestamp":1768286066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Global airways: a Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps"],"prefix":"10.3389","volume":"6","author":[{"given":"Vibeke","family":"Backer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Aan\u00e6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent Ivan","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hom\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Tidemandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Ovesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Madzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grethe","family":"Samuelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Hjelm","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Christian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Bruun","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorbj\u00f8rn","family":"Hermanrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Peter","family":"Schousboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Korsgaard","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Vrelits","family":"Filtenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preben","family":"Hom\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cea.14592","article-title":"Global incidence and prevalence of chronic rhinosinusitis: a systematic review","volume":"55","author":"Min","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: the skovde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1164\/rccm.202004-1013ED","article-title":"Blood eosinophil-directed management of airway disease. The past, present, and future","volume":"202","author":"Pavord","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/COPD.S74645","article-title":"Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units","volume":"10","author":"Sundh","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4193\/Rhino16.126","article-title":"The effect of endoscopic sinus surgery on quality of life and absenteeism in patients with chronic rhinosinuitis\u2014a multi-centre study","volume":"55","author":"Sahlstrand-Johnson","year":"2017","journal-title":"Rhinology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4193\/Rhin20.480","article-title":"The potential role of biological treatment of chronic rhinosinusitis with nasal polyps: a nationwide cohort study","volume":"59","author":"Eriksen","year":"2021","journal-title":"Rhinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/lary.27815","article-title":"Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study","volume":"129","author":"Alsharif","year":"2019","journal-title":"Laryngoscope"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/coa.13431","article-title":"Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis?","volume":"44","author":"Sahlstrand-Johnson","year":"2019","journal-title":"Clin Otolaryngol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000445151","article-title":"Oral therapeutics for rhinosinusitis with nasal polyposis","volume":"79","author":"Thomas","year":"2016","journal-title":"Adv Otorhinolaryngol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2500\/ajra.2015.29.4178","article-title":"Management of chronic rhinosinusitis with nasal polyps and coexisting asthma: a systematic review","volume":"29","author":"Rix","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","article-title":"Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/alr.23302","article-title":"The placebo effect in randomized-controlled trials of medical treatments for chronic rhinosinusitis: a systematic review and meta-analysis","volume":"14","author":"Pipaliya","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jaip.2022.09.043","article-title":"Chronic rhinosinusitis outcome registry (chrinosor): establishment of an international outcome registry driven by mhealth technology","volume":"11","author":"Seys","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.70032","article-title":"Two-year turning point with dupilumab in CRSwNP: control, remission, and tapering dosage","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/Rhin23.415","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.otohns.2006.09.014","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"135","author":"Meltzer","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (grade) and real-world evidence","volume":"145","author":"Bousquet","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"27768","DOI":"10.3402\/ecrj.v2.27768","article-title":"Diagnostic work-up in patients with possible asthma referred to a university hospital","volume":"2","author":"Backer","year":"2015","journal-title":"Eur Clin Respir J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1680703","DOI":"10.3389\/falgy.2025.1680703","article-title":"Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a delphi study to define key variables for the invent registry","volume":"6","author":"Backer","year":"2025","journal-title":"Front Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00405-024-09027-8","article-title":"Effects of mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study","volume":"282","author":"Orlando","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","article-title":"Omalizumab treatment in uncontrolled asthma and CRSwNP patients, with previous endoscopic sinus surgery, to improve quality of life and endoscopic outcomes: a two-year real-life study","volume":"23","author":"Maza-Solano","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","article-title":"Dupilumab (dupixent((r))) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany","volume":"280","author":"Jansen","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1159\/000514262","article-title":"Real-life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis","volume":"182","author":"Meier","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2407523","DOI":"10.1080\/07853890.2024.2407523","article-title":"Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience","volume":"56","author":"Santus","year":"2024","journal-title":"Ann Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.rmed.2013.09.007","article-title":"Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes","volume":"107","author":"Aasbjerg","year":"2013","journal-title":"Respir Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/jpm14091014","article-title":"Sinonasal outcomes obtained after 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and CRSwNP: a \u201creal-life\u201d observational study","volume":"14","author":"De Corso","year":"2024","journal-title":"J Pers Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/jcm11102684","article-title":"Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a \u201creal-life\u201d observational study in the first year of treatment","volume":"11","author":"De Corso","year":"2022","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaci.2024.10.016","article-title":"Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (chrinosor)","volume":"155","author":"Seys","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (synapse): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4193\/Rhino17.111","article-title":"Exhaled and nasal nitric oxide in chronic rhinosinusitis patients with nasal polyps in primary care","volume":"56","author":"Frendo","year":"2018","journal-title":"Rhinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e70032","DOI":"10.1002\/clt2.70032","article-title":"Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps","volume":"15","author":"Toppila-Salmi","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00408-023-00603-z","article-title":"Prevalence and severity distribution of type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis","volume":"201","author":"Khan","year":"2023","journal-title":"Lung"},{"key":"B47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/thx.2004.037978","article-title":"Inhaled corticosteroids and decline of lung function in community residents with asthma","volume":"61","author":"Lange","year":"2006","journal-title":"Thorax"},{"key":"B48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1081-1206(10)60940-4","article-title":"Quality of care in patients with asthma and rhinitis treated by respiratory specialists and primary care physicians: a 3-year randomized and prospective follow-up study","volume":"97","author":"Backer","year":"2006","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1735943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:34:28Z","timestamp":1768286068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1735943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":48,"alternative-id":["10.3389\/falgy.2025.1735943"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1735943","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1735943"}}